Athos Capital’s Moderna MRNA Stock Holding History

Athos Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-114,597	Closed	-$2.33M	–	40
2019 Q1	$2.33M	Sell	114,597 -17,171	-13%	-$319K	1.5%	13
2018 Q4	$2.01M	Buy	+131,768	New	+$2.17M	1.99%	13

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RWA

Ropes Wealth Advisors Boston, Massachusetts $515M AUM 21.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Athos Capital's MRNA Position: Q2 2019 in Review

Athos Capital sold out of Moderna (MRNA) in Q2 2019, closing a stake of 114,597 shares — an estimated $2.33M sold.

Athos Capital first reported a position in MRNA in Q4 2018 and held it in 2 quarters. The position peaked at $2.33M in Q1 2019. 138 funds tracked by Wall St. Rank hold MRNA as of Q2 2019.

Athos Capital reported no remaining Moderna position as of Q2 2019 after selling out during the quarter.
Athos Capital sold 114,597 Moderna shares in Q2 2019, an estimated $2.33M.
Athos Capital first reported a position in Moderna in Q4 2018 and held it in 2 quarters.
Athos Capital's Moderna position peaked at $2.33M in Q1 2019.
138 funds tracked by Wall St. Rank held Moderna as of Q2 2019.

Based on Athos Capital's 13F filing for Q2 2019, filed 13 Aug 2019.